Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 1/20 | 0.47 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.43 |
| ▸ | PGR | P06401 | 4/20 | 0.42 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.42 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 1/20 | 0.39 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | GABRA1 | P14867 | 1/20 | 0.34 |
| ▸ | GABRB2 | P47870 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.33 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.33 |
| ▸ | HTR2A | P28223 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 1/20 | 0.33 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7138992 | 0.89 | TDP1 (0.39) | PARP1NR3C1PGRNR3C2PTGS1 | |
| SCHEMBL6554491 | 0.85 | PARP1 (0.49) | PARP1NR3C1PGRNR3C2PTGS1 | |
| SCHEMBL12505563 | 0.82 | NR3C1 (0.48) | PARP1NR3C1PGRNR3C2PTGS1 | |
| SCHEMBL30862506 | 0.81 | PARP1 (0.47) | PARP1NR3C1PGRNR3C2AR | |
| SCHEMBL24650991 | 0.78 | NR3C1 (0.41) | PARP1NR3C1PGRNR3C2PTGS1 | |
| SCHEMBL24243099 | 0.78 | SSTR4 (0.51) | — | |
| SCHEMBL5516442 | 0.77 | NR3C1 (0.47) | PARP1NR3C1PGRNR3C2PTGS1 | |
| SCHEMBL20852602 | 0.77 | NR3C1 (0.40) | PARP1NR3C1PGRNR3C2PTGS1 | |
| SCHEMBL3366028 | 0.77 | PARP1 (0.47) | PARP1NR3C1PGRNR3C2AR | |
| SCHEMBL5520778 | 0.76 | NR3C1 (0.49) | PARP1NR3C1PGRNR3C2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 129 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11820770-B2 | P2X7 modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-11820766-B2 | Monoacylglycerol lipase modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-11-21 | — | — | US | disclosed |
| US-20230322788-A1 | IMIDAZOTRIAZINE AND PYRROLOPYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS | BEONE MEDICINES I GMBH (CH) | 2023-10-12 | — | — | US | disclosed |
| US-20230203059-A1 | MACROCYCLIC JAK INHIBITOR AND USES THEREOF | BIOPOLAR HONGYE (NANTONG) PHARMACEUTICAL CO. LTD. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-20230203059-A1 | MACROCYCLIC JAK INHIBITOR AND USES THEREOF | BIOPOLAR HONGYE (NANTONG) PHARMACEUTICAL CO. LTD. (CN) | 2023-06-29 | — | — | US | disclosed |
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KUMQUAT BIOSCIENCES INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KUMQUAT BIOSCIENCES INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-11 | — | — | US | disclosed |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | DEAN ANTHONY W | 2007-03-01 | — | — | US | disclosed |
| US-20070037855-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | ALZHEIMER'S INSTITUTE OF AMERICA, INC. | 2007-02-15 | — | — | US | disclosed |
| EP-0891346-B1 | DIHYDROBENZOFURAN COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | UNIV VANDERBILT (US) | 2004-05-12 | — | — | EP | disclosed |
| EP-0891346-A1 | DIHYDROBENZOFURAN COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | THE PROCTER & GAMBLE COMPANY (US) | 1999-01-20 | — | — | EP | disclosed |
| US-5674891-A | ANALGESICS WITH SIDE EFFECT REDUCTION | THE PROCTER & GAMBLE COMPANY (US) | 1997-10-07 | — | — | US | disclosed |
| US-5672620-A | ANALGESICS, ANTIARTHRITIC AGENT | THE PROCTER & GAMBLE COMPANY (US) | 1997-09-30 | — | — | US | disclosed |
| US-5656661-A | ANALGESICS | THE PROCTER & GAMBLE COMPANY (US) | 1997-08-12 | — | — | US | disclosed |
| WO-1997028148-A1 | DIHYDROBENZOFURAN COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | THE PROCTER & GAMBLE COMPANY (US) | 1997-08-07 | — | — | WO | disclosed |
| EP-0773939-A1 | DIHYDROBENZOFURAN AND RELATED COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | THE PROCTER & GAMBLE COMPANY (US) | 1997-05-21 | — | — | EP | disclosed |
| WO-1996003396-A1 | DIHYDROBENZOFURAN AND RELATED COMPOUNDS USEFUL AS ANTI-INFLAMMATORY AGENTS | THE PROCTER & GAMBLE COMPANY (US) | 1996-02-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11648254-B2 | Substituted pyrido[2,3-d]pyrimidines as inhibitors of Ras pathway signaling | KRAS, NRAS, BRAF | PARP1 856/4885NR3C1 3566/4885PGR 2033/4885 |
| US-20230145249-A1 | Monoacylglycerol Lipase Modulators | MGLL, LPL, PNLIP | PARP1 2910/4885NR3C1 1044/4885PGR 846/4885 |
| US-20070037855-A1 | Compounds for inhibiting beta-amyloid production and methods of identifying the compounds | APP, PSEN1, PSEN2 | PARP1 3996/4885NR3C1 3035/4885PGR 3580/4885 |
| US-20230322788-A1 | IMIDAZOTRIAZINE AND PYRROLOPYRIMIDINE DERIVATIVES AS KRAS G12C INHIBITORS | KRAS, NRAS, HRAS | PARP1 765/4885NR3C1 2332/4885PGR 3289/4885 |
| US-20230203059-A1 | MACROCYCLIC JAK INHIBITOR AND USES THEREOF | JAK3, JAK2, JAK1 | PARP1 1815/4885NR3C1 2112/4885PGR 1761/4885 |
| US-20070049570-A1 | Quinoline derivatives as phosphodiesterase inhibitors | PDE3B, PDE4B, PDE4A | PARP1 794/4885NR3C1 2737/4885PGR 3285/4885 |
| US-11820770-B2 | P2X7 modulators | P2RX2, P2RX7, P2RY2 | PARP1 2827/4885NR3C1 1889/4885PGR 1170/4885 |
| US-11820766-B2 | Monoacylglycerol lipase modulators | MGLL, LPL, PNLIP | PARP1 2910/4885NR3C1 1044/4885PGR 846/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.